

KOPRAN LIMITED
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31st DECEMBER, 2013

Part I	Quarter ended						(₹. in lakhs)
Particulars	Quarter ended			Nine Months ended		Year ended	
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Net Sales / Income from Operations	7628	7854	5633	21292	16891	24330	
Other Operating Income	173	237	142	570	457	692	
Total Income from operations	7801	8091	5775	21862	17348	25022	
Expenditure							
Changes in Inventories of Finished Goods, Work-in- Progress and stocks-in-trade	204	(371)	(309)	(423)	(708)	(408)	
Cost of Materials Consumed	4563	4968	3813	13400	11,255	15,823	
Purchase of Stock-in-trade	219	82	-	361	-	-	
Employee Benefits Expenses	611	615	536	1750	1,405	2,048	
Depreciation	315	308	305	926	903	1,208	
Other Expenses	1240	1350	1038	3580	2,989	4,129	
Total Expenses	7152	6952	5383	19594	15,844	22,800	
Profit (Loss) from operations before other income, interest and exceptional items	649	1,139	392	2,268	1,504	2,222	
Other Income	18	2	68	22	160	205	
Foregin Exchange Gain/ (Loss)	1	(263)	50	(158)	(27)	(33)	
Profit (Loss) before interest and exceptional items	668	878	510	2,132	1,637	2,394	
Finance Cost	361	375	284	1,043	837	1,188	
Profit (Loss) before exceptional items	307	503	226	1,089	800	1,206	
Exceptional items	-	-	-	-	-	-	
Profit (Loss) before tax	307	503	226	1,089	800	1,206	
Less :Tax expenses	-	-	-	-	-	-	
Net Profit for the period	307	503	226	1,089	800	1,206	
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905	3,905	3,905	
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	8,048	
Earning Per Share (EPS) before and after Exceptional Item							
a) Basic	0.79	1.29	0.58	2.79	2.05	3.09	
b) Diluted	0.79	1.29	0.58	2.79	2.05	3.09	
Part II							
(A) PARTICULARS OF SHAREHOLDING							
Public shareholding							
Number of shares	23753463	23956538	25809523	23753463	25809523	25510073	
Percentage of shareholding	60.83%	61.35%	66.09%	60.83%	66.09%	65.33%	
Promoters and Promoter Group Shareholding							
a) Pledged / Encumbered							
Number of shares	3352500	3352500	552500	3352500	552500	1852500	
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	21.92%	22.21%	4.17%	21.92%	4.17%	13.68%	
Percentage of shares (as a % of the total share capital of the company)	8.59%	8.59%	1.42%	8.59%	1.42%	4.74%	
b) Non - encumbered							
Number of shares	11943513	11740438	12687453	11943513	12687453	11686903	
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	78.08%	77.79%	95.83%	78.08%	95.83%	86.32%	
Percentage of shares (as a % of the total share capital of the company)	30.58%	30.06%	32.49%	30.58%	32.49%	29.93%	
(B) INVESTOR COMPLAINTS	3 Months ended 31/12/2013						
Pending at the beginning of the quarter							
Received during the quarter							
Disposed off during the quarter							
Remaining unresolved at the end of the quarter							

Reporting of Segment wise Revenue, Result and Capital Employed						
Particulars	Quarter ended			Nine Months ended		Year ended
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
1. Segment Revenue	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Pharamaceutical	8,019	8,207	5,947	22,337	17,905	25,734
(b) Consumer Care Division	67	75	-	185	-	-
Total	8,086	8,282	5,947	22,522	17,905	25,734
Less : Inter-Segment Revenue	-	-	-	-	-	-
Less : Excise Duty	285	191	172	660	557	712
Net Sales/ Income from Operation	7,801	8,091	5,775	21,862	17,348	25,022
2. Segment Results						
(a) Pharamaceutical	742	951	510	2,308	1,637	2,394
(b) Consumer Care Division	(74)	(73)	-	(176)	-	-
Total	668	878	510	2,132	1,637	2,394
Less: Finance Cost	361	375	284	1,043	837	1,188
Total Profit Before Tax	307	503	226	1,089	800	1,206
3. Capital Employed						
(a) Pharamaceutical	21,014	19,827	17,237	21,014	17,237	17,631
(b) Consumer Care Division	258	196	-	258	-	-
(c) Others (Unallocated)	5,425	5,424	5,403	5,425	5,403	5,419
Total	26,697	25,447	22,640	26,697	22,640	23,050

Notes:-


(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 13th February, 2014. Limited review has been carried out by statutory auditor of the company.

(2) Auditors observation:

a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 31-12-2013 amounting to Rs. 5238.42 Lacs, (as at 31-12-2012 Rs 5215.99 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.

(3) Figures for the previous accounting period have been regrouped wherever necessary.

KOPRAN LIMITED



Surendra Somani
Executive Vice Chairman

Place : Mumbai
Date: 13-02-2014